Celcuity rises as analyst lifts target to $125 ahead of Q2 data, July PDUFA
Celcuity shares are higher as investors react to a fresh bullish analyst update tied to upcoming Phase 3 data timing and a key FDA decision date. The stock is also seeing continued positioning ahead of a July 17, 2026 PDUFA deadline for gedatolisib.
1. What’s moving CELC today
Celcuity (CELC) is up about 3% as the market prices in a renewed wave of bullish expectations ahead of major 2026 catalysts for its lead program, gedatolisib. The latest spark is a recently published analyst note raising a price target to $125 while reiterating a Buy rating, citing clearer timing for topline disclosure from the company’s Phase 3 program and a tightening catalyst calendar into mid-2026. (investing.com)
2. The near-term catalyst setup: Q2 data window and July FDA deadline
Investor focus remains squarely on Celcuity’s Phase 3 VIKTORIA program and the regulatory path for gedatolisib. The same analyst update highlighted management’s refined expectations for when topline data will be shared (now framed within the second quarter of 2026), while also pointing investors to a July 17, 2026 PDUFA date as the next major binary event. (investing.com)
3. Positioning signals from large holders and recent company communications
Separately, a recent amended Schedule 13D/A showed Baker Bros.-related entities reporting beneficial ownership up to 19.99% and raising the beneficial-ownership limitation tied to certain prefunded warrants (effective May 20, 2026), a disclosure that can reinforce perceptions of institutional sponsorship even though the filing states no new securities were acquired in connection with the change. Celcuity also recently pointed investors to its corporate update cadence via its financial results webcast schedule, keeping attention on incremental updates as catalysts approach. (stocktitan.net)